News from sangart, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 08, 2012, 14:12 ET
Sangart, Inc. logo.  (PRNewsFoto/Sangart, Inc.)

Sangart Completes Patient Enrollment In Phase 2B Clinical Trial Of MP4OX In Traumatic Hemorrhagic Shock Patients

Sangart, Inc., a global biopharmaceutical company dedicated to developing rescue therapies for patients in ischemic crisis, today announced the...

May 24, 2012, 12:00 ET
Sangart, Inc. logo.  (PRNewsFoto/Sangart, Inc.)

Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock

Sangart, Inc., a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute...

Feb 15, 2012, 10:49 ET

Sangart Enhances Leadership Team Bringing Superior Depth of Expertise

Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen-therapeutic...

Jan 12, 2012, 14:29 ET

Sangart lance l'Étude de Phase 1b de MP4CO chez les patients affectés de l'anémie falciforme

Sangart, Inc., une société biopharmaceutique international engagée dans le développement de médicaments conçus pour...

Jan 12, 2012, 14:24 ET

Sangart inicia la Fase 1b de un Estudio de MP4CO en pacientes con anemia depranocítica

Sangart, Inc., una compañía biofarmacéutica global dedicada al desarrollo de valiosos medicamentos específicamente creados para...

Jan 12, 2012, 13:52 ET

Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease

 Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion...

Jun 14, 2011, 09:00 ET

Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and...

Apr 19, 2011, 14:00 ET

Sangart Announces Closing of $50 Million Series G Financing

Sangart, Inc., today announced that it recently received more than $50 million in new equity funding from existing investors, led by Leucadia...

Dec 06, 2010, 09:00 ET

Sangart, Inc. Announces Cooperative Research and Development Agreement With the U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and...

Nov 15, 2010, 12:00 ET

Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease

SAN DIEGO, Nov. 15, 2010 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines...

Oct 06, 2010, 09:00 ET

Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma

Sangart, Inc., today announced that it has been awarded a $1.1 million grant from the U.S. Department of Defense to support the development of its...

Aug 31, 2010, 09:00 ET

Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients

Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely...

Jun 29, 2010, 15:30 ET

Sangart, Inc. Completes Enrollment in Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients

Sangart, Inc., today announced that enrollment was completed in a Phase IIa clinical study of MP4OX (oxygenated pegylated hemoglobin) in severely...

Dec 09, 2009, 14:00 ET

Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion...

Dec 09, 2009, 11:00 ET

Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion...

Mar 12, 2009, 09:30 ET

Sangart, Inc. Completes Series F Funding Round

Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen therapeutics, today...

Jan 07, 2009, 21:19 ET

Sangart, Inc. Announces Key Executive Appointments and Company Restructuring

Business Units Refocused on Additional Clinical Studies Planned for Hemospan(R) Sangart, Inc., a privately held biopharmaceutical company focused...

Jan 07, 2009, 10:00 ET

Sangart, Inc. Announces Key Executive Appointments and Company Restructuring

Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen-therapeutic agents,...

Jun 11, 2008, 01:00 ET

Sangart Responds to Report Published in the Journal of the American Medical Association and Provides Update on Phase III Trials of Hemospan(R)

SAN DIEGO, June 11 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and...

May 19, 2008, 01:00 ET

Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent

SAN DIEGO, May 19 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge